Ardelyx, Inc. (ARDX): Elizabeth A Grammer , SVP, General Counsel of Ardelyx, Inc. sold 6,859 shares on Sep 19, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $11.21 per share for a total value of $76,880.48 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 20, 2016, Harry R Weller (10% owner) purchased 1,527,301 shares at $8.73 per share price.On Jul 20, 2016, Ravi Viswanathan (10% owner) purchased 1,527,301 shares at $8.73 per share price.Also, On Jul 20, 2016, Peter W. Sonsini (10% owner) purchased 1,527,301 shares at $8.73 per share price.On Jul 20, 2016, Joshua Makower (10% owner) purchased 1,527,301 shares at $8.73 per share price.
Ardelyx Inc: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Ardelyx Inc which led to swings in the share price. The shares opened for trading at $11.34 and hit $11.64 on the upside , eventually ending the session at $11.42, with a gain of 1.78% or 0.2 points. The heightened volatility saw the trading volume jump to 1,65,520 shares. The 52-week high of the share price is $22.4799 and the company has a market cap of $540 M . The 52-week low of the share price is at $6.36.
Ardelyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery development and commercialization of minimally-systemic small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat cardio-renal GI and metabolic diseases. The Company utilizing its platform discovered and designed its lead product candidate tenapanor which in clinical studies has demonstrated the ability to improve the symptoms of constipation-predominant irritable bowel syndrome (IBS-C) and to reduce the absorption of both dietary sodium and phosphorus. The Company in collaboration with AstraZeneca has completed a Phase IIb clinical trial evaluating tenapanor in patients with IBS-C. It also has other product candidates under development such as RDX002 for the treatment of Hyperphosphatemia RDX009 for the treatment of IBD Short Bowel Syndrome and non-alcoholic steatohepatitis (NASH) and RDX013 for the treatment of hyperkalemia.